Lynnet Koh

ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA.

Rincon Pharmaceuticals, Inc. develops human therapeutic proteins. It develops and manufactures both partnered and proprietary products. The company was founded by Bruce D. Steel in 2004 and is headquartered in San Diego, CA.

Batu Biologics, Inc. operates as an immunotherapy company. It develops therapeutics that addresses the multi-factorial and multi-dimensional nature of cancer. The company was founded by Samuel C. Wagner, Thomas Ichim and Dimitri Theofilopoulos and is headquartered in San Diego, CA.

Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies.

Scancell Ltd. researches and develops techniques for isolating foetal cells from a maternal blood sample. The company was founded by Lindy Durrant in 1997 and is headquartered in Nottingham, the United Kingdom.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada.

BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA.

Celgene Research & Development manufactures biopharmaceutical products. It develops discovery programs that regulate inflammatory, cardiovascular, neurological diseases, and cancer. It is a subsidiary of Celgene Corp. The company is headquartered in San Diego, CA.

Novation Pharmaceuticals, Inc. operates as a biotechnology research and development company. It provides modulation of intracellular messenger RNA (mRNA) to identify new small-molecule therapies to treat serious diseases. The company was founded by Dominique Cheneval and Tania Kastelic and is headquartered in Burnaby, Canada.

Juvenile Diabetes Research Foundation Ltd. is a British company that engages in the prevention, treatment, causes, and cure for diabetes. The CEO of the non-profit company is Karen Addington.

The American company was founded by Karl L. Mettinger and Kent Persson, with Karl L. Mettinger serving as CEO since incorporation.

Capella Therapeutics, Inc. develops small molecule drugs to treat cancer and inflammatory diseases. The private company is based in San Diego, CA. The company was founded in 2014 by Yun Long. Yun Long has been the CEO since 2014.

Dendreon Pharmaceuticals, Inc. discovers, develops and commercializes novel products for the treatment of cancer. The company is headquartered in Olympia, WA.

Habit DX, Inc. manufactures clinical measuring and monitoring tools. The private company is based in San Francisco, CA.

NeuraMetrix, Inc. manufactures clinical measurement tools for monitoring brain health. The company was founded by Jan Samzelius and Christian Olsson in 2012 and is headquartered in Palo Alto, CA.

Evolve Biologics, Inc. is a Canadian plasma-derived therapeutics company headquartered in Mississauga, CA. The company is focused on commercializing a portfolio of product candidates, including intravenous immunoglobulin (IVIG) and human serum albumin (HSA), both of which are in advanced stages of regulatory approval with the FDA and Health Canada. Evolve's state-of-the-art facility is the first to use its innovative and proprietary technology, Plasmacap EBA®, to commercially produce plasma-derived therapeutics. The company has recently appointed James V. Caggiano as CEO, who brings nearly 30 years of experience in the biotech, pharma, and medical device industries.